FDA Expands Indication of Antiviral Therapy to Include Post-Exposure Influenza Prevention
November 23, 2020 09:45pm
Regardless the trend of previous yearsâ€™ strains or mutations, manufacturers are working on limited clinical insight as to how best manage the upcoming yearâ€™s flu.
, vaccine manufacturers have finalized work for the next flu season.
A little more than 6 months since researchers addressed the mutated H3N2 strain that resulted inabnormally high rates of influenza outbreak in the US
Sanofi Pasteur, Sanofi’s vaccine division stationed in Swiftwater, PA, has manufactured about
, with the first round of shipments anticipated to reach physicians and customers throughout August.
The cyclical vaccine production process is bookended by the newest strain’s distribution in the late summer, and the selection of strains by the World Health Organization (WHO) and the CDC on March 1. Regardless the trend of previous years’ strains or mutations, manufacturers are working on limited clinical insight as to how best manage the upcoming year’s flu.
David Greenberg, MD, associate vice president and regional medical head of North America for Sanofi, told
® it’s difficult enough to predict whether the flu will spread more in October, or later in the season like January—let alone predicting which strain will dominate in cases.
“People try to get some idea from what’s happening now in the Southern Hemisphere, but it’s hard to predict,” Greenberg said. “As to whether 1 particular strain will be dominant or another, we don’t know. That’s why we have 4 strains.”
To read the full article, visitMdMag.com.